Richard Markus Sells 4,494 Shares of Arcus Biosciences (NYSE:RCUS) Stock

by · The Cerbat Gem

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) insider Richard Markus sold 4,494 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $99,587.04. Following the transaction, the insider owned 65,647 shares of the company’s stock, valued at approximately $1,454,737.52. This trade represents a 6.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Richard Markus also recently made the following trade(s):

  • On Tuesday, December 16th, Richard Markus sold 5,052 shares of Arcus Biosciences stock. The stock was sold at an average price of $21.88, for a total value of $110,537.76.

Arcus Biosciences Price Performance

NYSE:RCUS opened at $21.99 on Friday. The stock has a 50-day simple moving average of $21.10 and a 200 day simple moving average of $14.13. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $26.40. The company has a market cap of $2.37 billion, a PE ratio of -6.39 and a beta of 0.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The firm had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business’s revenue was down 45.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.00) EPS. On average, sell-side analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Woodline Partners LP increased its holdings in Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after buying an additional 1,603,367 shares during the period. Vanguard Group Inc. increased its stake in Arcus Biosciences by 24.1% in the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after acquiring an additional 1,298,584 shares during the last quarter. RA Capital Management L.P. acquired a new position in Arcus Biosciences during the first quarter valued at approximately $8,920,000. Wellington Management Group LLP bought a new stake in Arcus Biosciences during the first quarter worth $8,500,000. Finally, Bank of America Corp DE boosted its holdings in shares of Arcus Biosciences by 173.5% in the 3rd quarter. Bank of America Corp DE now owns 1,360,781 shares of the company’s stock valued at $18,507,000 after purchasing an additional 863,162 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

  • Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high‑visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy‑side attention ahead of catalysts. Arcus to Present at JPM
  • Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
  • Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short‑term selling pressure. See CEO SEC filing for details. CEO Form 4
  • Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on RCUS shares. Wall Street Zen raised shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Wedbush set a $35.00 target price on Arcus Biosciences and gave the stock an “outperform” rating in a report on Wednesday, October 29th. HC Wainwright raised their price target on Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Bank of America boosted their price target on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Finally, UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a report on Monday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.89.

Get Our Latest Report on RCUS

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.

Further Reading